Nabriva Therapeutics to Present Data at ASM Microbe Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO™ (fosfomycin) for injection to Treat Complicated Urinary Tract Infections (cUTIs)


You May Also Like

Precision Therapeutics to Hold Business Update Conference Call on April 2, 2018

MINNEAPOLIS, March 26, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the ...